Elevance Health Surges 4.79 with $1.05B Volume as Top 500 Stock Gains Institutional Momentum

On August 15, 2025, Elevance Health (ELV) surged 4.79% to $303, with a trading volume of $1.05 billion, marking a 66.05% increase from the previous day. The stock’s performance followed a reversal from prior losses linked to rising medical costs, supported by positive technical indicators such as a KDJ Golden Cross and Marubozu patterns. Institutional confidence grew as Boston Partners increased holdings by 241.3%, and CEO Gail Boudreaux purchased 8,500 shares. The company also announced a $0.14 quarterly dividend, maintaining a 90% profit margin despite reduced premium share growth compared to 2024.

Elevance reported Q2 2025 earnings on July 17, with an EPS of $8.84, below the $9.30 analyst estimate. Quarterly revenue rose 14.3% year-over-year to $49.42 billion, exceeding expectations. The trailing P/E ratio stands at 12.37, with projected EPS growth of 14.99% for the next year. Earnings for Q3 2025 are expected on October 16, with analysts forecasting $9.30 per share. The company’s FY 2025 guidance of $32.37–$39.22 EPS aligns with current performance trends.

A strategy of buying the top 500 stocks by daily trading volume and holding for one day from 2022 to present generated a total profit of $10,720. The returns remained moderate, with fluctuations influenced by market dynamics over the period.